As of 14 Oct 2026, tenvie has raised $200M across 1 verified round on record; latest: $200 million funding round led by Arch Venture Partners, F-Prime Capital and 1 other, announced 8 Jan 2025.
Precision-engineered small molecule therapies for neurological and peripheral diseases targeting patients and caregivers.
tenvie.comBiotech
2 sources
No source labels the financing by stage. The sources name no additional participating investors; South San Francisco is a dateline, not a stated headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-01-08 | Arch Venture Partners, F-Prime Capital, Mubadala Capital | No recent discussion |
2 sources [ VERIFIED ] read against 2 sources No source labels the financing by stage. The sources name no additional participating investors; South San Francisco is a dateline, not a stated headquarters. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: tenvie.com, globenewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 2 sources·[ BRANDING ]logo and colour from the homepage | ||||